Routine initial ownership filing for a new insider. No trading signal. Monitor future Form 4 filings for any open-market purchases or sales by Diaz.
MRK drugs
MRK drug pipeline →- ● ENFLONSIA 4/10 Approved · PDUFA date Mar 22, 2027
- ● IDVYNSO 4/10 Approved · PDUFA date Apr 22, 2027
- ▲ sac-TMT 6/10 Filed/PDUFA (Phase 3 data complete; BLA under priority review) · PDUFA date Jun 15, 2027
- ● GARDASIL 4/10 Approved
- ● LAGEVRIO 4/10 EUA (Emergency Use Authorization) / Marketed
- 15 more · All MRK drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $144.67entry
- T+1 · 13d ago +3.93%α +2.28% · $150.36
- T+5 · 7d ago +2.34%α +2.92% · $148.05
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Paul J. Diaz filed a Form 3 initial statement of beneficial ownership with the SEC, reporting 200 shares of Merck common stock held directly and 96 shares held indirectly through a revocable trust. The filing is a routine Section 16 compliance requirement for a new officer or director and contains no material financial information.
Key Facts
- Paul J. Diaz filed Form 3 on 2026-11-03, reporting beneficial ownership as of 2026-11-01.
- Direct holdings: 200 shares of Merck common stock.
- Indirect holdings: 96 shares held through Reporting Person's Revocable Trust.
- The filing includes a Power of Attorney authorizing Jennifer Zachary, Jon Filderman, and Kelly Grez to file Section 16 reports on his behalf.
Financial Impact
No material financial impact; holdings of 296 shares are negligible relative to Merck's $361B market cap.
Risk Factors
- No material risks identified; this is a standard compliance filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0000310158-26-000243 |
| Document: 0000310158-26-000243-index-headers.html | 0000310158-26-000243 |
| Document: 0000310158-26-000243-index.html | 0000310158-26-000243 |
| Document: 0000310158-26-000243.txt | 0000310158-26-000243 |
Track record
34 reports on MRK
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +16.92% at T+20 after the Aug 6, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $147.76 Now $144.46 −2.23% settles Feb 11
- Nov 9, 20268d ago PTAB Trial Neutral 2/10 Entry $148.05 Now $144.46 −2.42% settles Feb 8
- Nov 3, 202613d ago 3 Neutral 2/10 Viewing Entry $144.67 Now $144.46 −0.15% settles Feb 1
- Nov 3, 202613d ago Institutional Cluster Bearish 4/10 Entry $144.67 Now $144.46 +0.15% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $144.67 Now $144.46 −0.15% settles Feb 1
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $146.33 Now $144.46 −1.28% settles Jan 27
- Oct 22, 202625d ago 3/A Neutral 1/10 Entry $145.27 Now $144.46 −0.56% settles Jan 21
- Oct 21, 202627d ago PTAB Trial Neutral 3/10 Entry $147.24 Now $144.46 −1.89% settles Jan 20
- Oct 15, 20264w ago PTAB Trial Bullish 6/10 Entry $145.95 Now $144.46 −1.02% settles Jan 13
- Oct 15, 20264w ago PTAB Trial Bullish 5/10 Entry $145.95 Now $144.46 −1.02% settles Jan 13
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers